Can Supplements Help Uterine Fibroids? Here Is What the Research Actually Shows

EGCG — epigallocatechin gallate, the primary catechin in green tea — has produced the most striking fibroid-specific clinical data in the supplement literature. A randomized controlled trial by Wahab et al. compared EGCG supplementation at 400mg to placebo over 4 months in women with uterine fibroids. The EGCG group showed a −32.6% reduction in total fibroid volume; the placebo group's fibroids continued to grow. Symptom severity scores also improved significantly in the treatment group.

The proposed mechanisms are multiple: EGCG inhibits VEGF (vascular endothelial growth factor), which fibroids require to build their blood supply. It also activates apoptosis in fibroid smooth muscle cells while sparing normal myometrium, suggesting some selectivity. Additionally, EGCG has anti-aromatase properties — it inhibits local estrogen production. At 400mg, it is well-tolerated with the main caveat being that high-dose green tea extract (above 800mg EGCG) has been associated with liver enzyme elevation in rare cases, so the 400mg dose used in the fibroid trial is the appropriate target, not higher.

Quercetin at 500mg works on fibroid cell biology at the proliferation level. In vitro studies have shown quercetin inhibits the growth of human uterine fibroid cells by modulating several growth signaling pathways, including mTOR and Wnt/β-catenin — both of which are aberrantly active in fibroid tissue. It also has anti-inflammatory effects and inhibits histamine release, which may contribute to reduced heavy bleeding. The clinical translation data is still emerging, but the mechanistic logic is solid and quercetin is exceptionally safe at this dose.

DIM (diindolylmethane) at 200mg addresses estrogen metabolism directly. Fibroids thrive on estrogen — specifically, the more potent 16-OH estrone metabolites that stimulate cell growth. DIM shifts the balance of estrogen metabolites toward the 2-OH pathway, producing estrogen forms that are less proliferative. This is the same mechanism relevant in estrogen-dominant conditions more broadly, but for fibroids it targets the hormonal driver of growth itself. DIM does not suppress estrogen production — it redirects it toward less stimulatory metabolites, which is meaningful for estrogen-sensitive tissue like fibroids.

Vitamin D3's role in fibroid biology is among the more interesting recent research threads. Fibroid cells express vitamin D receptors (VDR), and several studies have shown that vitamin D signaling inhibits fibroid cell proliferation and promotes differentiation. Critically, multiple epidemiological studies have found an inverse relationship between vitamin D status and fibroid prevalence — women with higher serum 25(OH)D have lower rates of diagnosed fibroids. The association is especially pronounced in Black women, who have both the highest fibroid burden and the highest rates of vitamin D deficiency (due to melanin's effect on cutaneous vitamin D synthesis).

Animal model studies have shown that vitamin D supplementation reduces fibroid tumor size. Human RCT data is still limited, but the biological mechanism is compelling and the supplementation risk is minimal. At 2000 IU daily, it replenishes deficiency in most people without approaching toxicity thresholds. For women with fibroids, getting a 25(OH)D level checked and ensuring it is above 40 ng/mL is one of the most rational, low-cost interventions available.